A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Sponsor

MedImmune LLC (Industry)

Overall Status

Terminated

CT.gov ID

NCT02556463

Collaborator

(none)

Enrollment

Locations

Arms

35.7

Actual Duration (Months)

5.3

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To evaluate MEDI9197 when administered by intratumoral injection to subjects with solid tumors and in combination with durvalumab in subjects with solid tumors.

Condition or Disease	Intervention/Treatment	Phase
Solid Tumors CTCL Cancer	Drug: MEDI9197 Biological: durvalumab	Phase 1

Detailed Description

This is a multicenter, open-label study to evaluate the TLR 7/8 agonist MEDI9197 delivered by IT injection to subjects with solid tumors and in combination with durvalumab in subjects with solid tumors. The study has a dose escalation design using mTPI-2 to evaluate a range of doses.

Study Design

Study Type:

Interventional

Actual Enrollment :

53 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Actual Study Start Date :

Nov 4, 2015

Actual Primary Completion Date :

Oct 26, 2018

Actual Study Completion Date :

Oct 26, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Escalation MEDI9197 MEDI9197	Drug: MEDI9197 Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)
Experimental: Escalation MEDI9197 with durvalumab MEDI9197 in combination with durvalumab	Drug: MEDI9197 Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6) Biological: durvalumab Subjects will receive durvalumab every 4 weeks Other Names: MEDI4736
Experimental: Escalation MEDI9197 durvalumab radiation MEDI9197 in combination with durvalumab and palliative radiation	Drug: MEDI9197 Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6) Biological: durvalumab Subjects will receive durvalumab every 4 weeks Other Names: MEDI4736
Experimental: MEDI9197 with palliative radiation MEDI9197 in combination with palliative radiation	Drug: MEDI9197 Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)

Outcome Measures

Primary Outcome Measures

Safety and tolerability as determined by assessment of dose limiting toxicities and the maximum tolerated dose or maximal assessed dose per protocol of MEDI9197 when administered by intratumoral injection to subjects with solid tumor cancers [From time of informed consent through 4 weeks after last dose of investigational product]
The primary endpoint will be the number (%) of subjects with dose-limiting toxicities, adverse and serious adverse events and other safety parameters.
Safety and tolerability as determined by assessment of dose limiting toxicities and the maximum tolerated dose or maximal assessed dose per protocol of MEDI9197 when administered by intratumoral injection to subjects with CTCL [From time of informed consent through 6 months after last dose of investigational product]
The primary endpoint will be the number (%) of subjects with dose-limiting toxicities, adverse and serious adverse events and other safety parameters.
Safety & tolerability as determined by dose limiting toxicities and maximum tolerated or assessed dose of MEDI9197 administered by IT injection in combo with durvalumab and durvalumab plus palliative radiation to subjects with solid tumor cancers. [From time of informed consent through 90 days after last dose of investigational product]
The primary endpoint will be the number (%) of subjects with dose-limiting toxicities, adverse and serious adverse events and other safety parameters.

Secondary Outcome Measures

The maximum concentration of MEDI9197 after the first injection [Pre-dose to 24 hours post first dose]
The apparent terminal half-life of MEDI9197 [Pre-dose to 24 hours post first dose]
Percent change from baseline in cluster of differentiation 8 tumor infiltrating lymphocytes in tumor tissue [Baseline to Day 50]
Percent change from baseline in serum inflammatory cytokine levels [Pre-dose to end of study, up to 24 months]
Percent change from baseline in tumor measurements [Pre-dose to disease progression, up to 12 months]
Objective response rate [Pre-dose to end of study, up to 24 months]
Duration of response [Pre-dose to end of study, up to 24 months]
Percent change from baseline in CAILDS for subjects with CTCL [Pre-dose to disease progression, up to 12 months]
Percent change from baseline in mSWAT scored for subjects with CTCL [Pre-dose to disease progression, up to 12 months]
Percent change from baseline in Investigator Global Assessment (IGA) for subjects with CTCL [Pre-dose to disease progression, up to 12 months]
Percent change from baseline in Subject Global Assessment (SGA) for subjects with CTCL [Pre-dose to disease progression, up to 12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 99 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria for All Subjects (Parts 1, 2 and 3)

Written informed consent and any locally required authorizations.
Male and female subjects at least 18 years at the time of screening.
Adequate organ function within 14 days of enrollment confirmed by laboratory results.
Systemic corticosteroids at doses exceeding 12 mg/day prednisone or equivalent.
ECOG 0 or 1.
Highly effective method of contraception from the date of the screening pregnancy test, and continued precautions for 6 months after the final dose of investigational product.
Baseline Child-Pugh Score of A1 to B7.
Life expectancy ≥ 12 weeks, as estimated by Royal Marsden Hospital Score of 0 or 1 at baseline.
Subjects with hepatocellular carcinoma (HCC) are eligible if the tumor is defined as nodular type 1 or 2 only.

Additional Inclusion Criteria for Subjects in Parts 1 and 3

Metastatic/locally advanced solid tumor malignancy that has progressed on, is refractory to, or for which there is no standard of care therapy.
For subjects with cutaneous/subcutaneous lesions, subjects must have more than one measurable target lesion, at baseline, with a minimum of one lesion that meets protocol specified criteria.
For subjects with deep-seated lesions, subjects must have more than one measurable target lesion at baseline (RECIST v1.1), with a minimum of one deep-seated lesion suitable for image-guided injection and that meets protocol specified criteria.

Additional Inclusion Criteria for Subjects in Part 2 (Closed to Enrollment as of Protocol Amendment 6)

Clinical diagnosis of CTCL, including documentation of a skin biopsy with histological findings consistent with CTCL or unconfirmed diagnosis of CTCL with confirmation biopsy at screening.
Stage IB, IIA, or IIB disease: T1, T2 or T3 (patches, plaques or tumors) with measurable lesions.
Previous treatment with at least one standard therapy used to treat the stage of disease at study entry; Stage IB, IIA or IIB CTCL.
Measurable skin disease with at least 2 lesions amenable to response assessment.
At least one lesion must be amenable to injection, ie, ≥ 1.5 cm in the longest diameter.

Exclusion Criteria:

Any of the following would exclude the subject from participation in the study:

Subjects who have received prior immunotherapy [(including but not limited to CTLA-4, oncolytic virus, oncolytic peptide-all require 100 day washout), programmed death ligand (PDL)-1, or programmed cell death 1 antagonists-both require 14 day washout)] are NOT permitted to enroll, with protocol exceptions.
Pregnant or lactating.
Active bacterial, fungal, or viral infections, including chronic or active hepatitis B, chronic or active hepatitis C, or active hepatitis A. Prior documented infections must have resolved.
Active or prior documented autoimmune or inflammatory disorders, with exceptions per protocol. Includes known allergy to sesame oil and/or nuts.
Immune-deficiency states - myelodysplastic disorders, marrow failures, human immunodeficiency virus (HIV) infection, history of solid organ transplant or bone marrow allograft, or recent pregnancy.
Requires continuous (daily) anticoagulation or antiplatelet therapy (including anti aggregants), acetylsalicylic acid (ASA) or nonsteroidal anti-inflammatory drugs (NSAIDs).
History of coagulopathy resulting in uncontrolled bleeding or other bleeding disorders.
Rapidly progressing disease per protocol.
Untreated or uncontrolled central nervous system (CNS) involvement.
Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment; with exceptions per protocol.
Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v4.03 Grade 0 or 1, with exception of alopecia, vitiligo.
Uncontrolled concurrent illness.
Cardiac exclusions: New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled hypertension, acute coronary syndrome within 6 months, clinical important cardiac arrhythmia, mean QTC interval corrected for heart rate >500ms.
Major surgery within 4 weeks prior to study entry or still recovering from prior surgery.
Receipt of live, attenuated vaccine within 28 days prior to study entry.
Receipt of any systemic anticancer therapy not mentioned above within the last 2 weeks or 5 half-lives.
Cognitive disorder such that informed consent cannot be obtained directly from the subject
Subjects who have previously participated in this study and received MEDI9197, or concurrent enrollment in another clinical study involving an investigational treatment.
Subjects who have received prior TLR agonists, both systemic and topical.
Patients who have received prior therapeutic radiation within 28 days of dosing. All toxicities from prior radiotherapy must have resolved to ≤ Grade 1 or baseline prior to dosing.
Body weight < 35 kg
Subjects enrolling in Part 3 (ie, receiving durvalumab) must not have a history of interstitial lung disease or pneumonitis.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Research Site	San Francisco	California	United States	94115
2	Research Site	Aurora	Colorado	United States	80045
3	Research Site	Minneapolis	Minnesota	United States	55455
4	Research Site	Saint Louis	Missouri	United States	63110
5	Research Site	New York	New York	United States	10029
6	Research Site	Chapel Hill	North Carolina	United States	27599-7305
7	Research Site	Philadelphia	Pennsylvania	United States	19104
8	Research Site	Houston	Texas	United States	77030
9	Research Site	Toronto	Ontario	Canada	M5G 1Z6
10	Research Site	Villejuif		France	94805